About us

Actualizing the untapped potential of the innate immune system

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Corporate Presentation

Mechanism of Action video

Affimed’s fit-for-purpose ROCK® platform

Leveraging our proprietary fit-for-purpose ROCK® (Redirected Optimized Cell Killing) platform, we develop innate cell engagers that are capable of reactivating innate immune cells to kill cancer cells and have the potential to overcome the limitations of traditional therapies. A number of clinical and preclinical programs are ongoing to study innate cell engagers in both hematological and solid tumors.

learn more about our ROCK® platform

Our Pipeline

Diverse pipeline of innate cell engagers designed to activate innate immunity

Our differentiated preclinical and clinical pipeline comprises innate cell engagers designed to target both hematologic and solid tumors. Our CD16A-based innate cell engager AFM13 is the first to have reached the clinic and demonstrates evidence of a favorable safety profile and promising signs of therapeutic efficacy.

Innate Cell Engagers


Disease Target CD30
Peripheral T cell lymphoma (AFM13-202)
Phase 2
Transformed mycosis fungoides (AFM13-202)
Phase 2
CD30-positive T cell lymphoma (AFM13-102)
Phase 2
HL (post BV and post anti-PD-1) (AFM13-201)
Phase 2

AFM13 + adoptive NK cells

Disease Target CD30
CD30-positive lymphoma (AFM13-104)
Phase 1

AFM13 + anti-PD-1

Disease Target CD30
Hodgkin lymphoma (post BV) (AFM13-103)
Phase 1


Disease Target EGFR
Solid tumors (AFM24-101)
Phase 1

AFM24 + adoptive NK cells

Disease Target EGFR
Multiple solid tumors (AFM24-103)
Phase 1

AFM24 + anti-PD-L1

Disease Target EGFR
Multiple solid tumors (AFM24-102)
IND not required


Disease Target CD123
Acute Myeloid Leukemia


Disease Target Undisclosed
Solid tumors


Disease Target Undisclosed
Multiple Programs

ICE® + NK cell combination: co-vialed, cryopreserved, off-the-shelf

Disease Target Undisclosed
Affimed programs
Partnered programs

Selected posters & publications:

  • Wingert et al., mAbs 2021; 13(1):1950264: Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
  • Kerbauy et al., Clin Cancer Res 2021: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies
  • Bartlett et al., Blood 2020: A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Please see: Blood 2020; 136: 2401–2409.
  • Pahl et al., AACR 2021: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies View poster
  • Reusch et al., AACR 2020: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies View poster
  • Ellwanger et al., mAbs 2019: Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. Please see: mAbs 2019; 11:899-918.
  • Sawas et al., 15-ICML 2019: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) View poster
  • Oral Presentation: Ansell et al., ICML 2019: Investigating safety and preliminary efficacy of AFM13 plus Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure View poster
  • Bartlett et al., ASH 2018: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data View poster
  • Marin et al., ASH 2018: The CD30/CD16A Bispecific Innate Immune Cell Engager AFM13 Elicits Heterogeneous Single-cell NK Cell Responses and Effectively Triggers Memory Like (ML) NK Cells View poster
  • Wingert et al., ASH 2018: CD16A-Specific Tetravalent Bispecific Immuno-Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) by Macrophages View poster
  • Kluge et al., AACR 2018: Preclinical Characterization of the Bispecific EGFR/CD16A Innate Immune Cell Engager AFM24 for the Treatment of EGFR-Expressing Solid Tumors View poster

See all Publications & Posters


Affimed fosters and continues to seek partnerships that are in line with the company’s overall corporate strategy to continue to move its clinical programs forward, enhance the development of Affimed’s internal pipeline and to allow for the technological advancement of our platform to realize the full potential of innate immune cells in oncology.

read more about our partners

Management Team

Learn more about our experienced Management Team with a proven track record in biotech, pharma, product development and finance.


Supervisory Board

Learn more about our Supervisory Board comprised of seasoned experts from the pharmaceutical and biotech industry.

Supervisory Board